Zoetis (ZTS) Positioned Within Morgan Stanley’s 2026 Healthcare Playbook

Group 1 - Zoetis Inc. is recognized as one of the 15 Dividend Stocks with low payout ratios and strong upside potential [1] - Morgan Stanley has lowered its price target for Zoetis to $160 from $175 while maintaining an Overweight rating, highlighting the attractive opportunities in healthcare technology and providers for 2026 [2] - Zoetis received regulatory approval from Health Canada for Portela™ (relfovetmab injection), a treatment for osteoarthritis pain in cats, which provides three months of pain relief with a single injection [3][4] Group 2 - Clinical studies demonstrated that Portela effectively reduced osteoarthritis pain in cats and was well tolerated, including in those with early-stage kidney disease [4] - Zoetis operates as the world's largest animal health company, focusing on advancing care for animals and supporting animal well-being across both companion and livestock markets [5]